Alkermes plc. SEC 10-Q Report

Alkermes plc., a global biopharmaceutical company, has released its Form 10-Q report for the second quarter of 2025. The report provides a detailed overview of the company's financial performance and key business activities, reflecting both the challenges and achievements faced during the period. This summary highlights the essential financial metrics and operational developments that define Alkermes' performance in the biopharmaceutical industry.

Financial Highlights

Total Revenues: $390.7 million for the three months ended June 30, 2025, compared to $399.1 million for the same period in 2024, reflecting a decrease primarily due to lower manufacturing and royalty revenues.

Total Revenues: $697.2 million for the six months ended June 30, 2025, compared to $749.5 million for the same period in 2024, reflecting a decrease primarily due to lower manufacturing and royalty revenues.

Operating Income from Continuing Operations: $93.0 million for the three months ended June 30, 2025, compared to $109.9 million for the same period in 2024, primarily due to decreased revenues.

Operating Income from Continuing Operations: $106.8 million for the six months ended June 30, 2025, compared to $153.2 million for the same period in 2024, primarily due to decreased revenues.

Net Income from Continuing Operations: $87.1 million for the three months ended June 30, 2025, compared to $94.7 million for the same period in 2024, reflecting a decrease due to lower revenues.

Net Income from Continuing Operations: $109.6 million for the six months ended June 30, 2025, compared to $133.6 million for the same period in 2024, reflecting a decrease due to lower revenues.

Earnings Per Ordinary Share - Basic: $0.53 for the three months ended June 30, 2025, compared to $0.54 for the same period in 2024.

Earnings Per Ordinary Share - Basic: $0.67 for the six months ended June 30, 2025, compared to $0.76 for the same period in 2024.

Earnings Per Ordinary Share - Diluted: $0.52 for the three months ended June 30, 2025, compared to $0.53 for the same period in 2024.

Earnings Per Ordinary Share - Diluted: $0.65 for the six months ended June 30, 2025, compared to $0.75 for the same period in 2024.

Business Highlights

Revenue Segments: The company reported product sales, net, for VIVITROL, ARISTADA and ARISTADA INITIO, and LYBALVI. VIVITROL sales increased by $9.8 million in Q2 2025 compared to Q2 2024, while ARISTADA and ARISTADA INITIO sales increased by $15.3 million, and LYBALVI sales increased by $12.9 million.

Sales Units: There was a 14% increase in the number of LYBALVI units sold and a 2% increase for ARISTADA/ARISTADA INITIO in Q2 2025 compared to Q2 2024. However, VIVITROL saw a 1% decrease in units sold.

New Product Launches: In May 2025, U.S. Patent No. 12,311,027 was granted for ARISTADA, which relates to pharmaceutical compositions that confer long-term stability of the ARISTADA formulation.

Key Development Program: Alixorexton, a novel oral selective orexin 2 receptor agonist, is in development for narcolepsy and idiopathic hypersomnia. The phase 2 Vibrance-1 study achieved its primary endpoint, and a phase 3 program is planned.

Future Outlook: The company expects royalty revenues from the long-acting INVEGA products to continue to be lower in 2025 due to the expiration of the U.S. royalty on INVEGA SUSTENNA. Additionally, the company plans to initiate a phase 3 program for alixorexton following successful phase 2 results.

SEC Filing: Alkermes plc. [ ALKS ] - 10-Q - Jul. 29, 2025